Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1845 • ACR Convergence 2025
Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Noe Macias-Segura¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) significantly increases the risk of premature atherosclerosis, contributing to long-term morbidity and mortality. Traditional cardiovascular risk factors do not fully…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Soziema Salia¹, Boniface Mensah², Ufuoma Mamoh¹, Gilava Hedayati¹, Terrylyna Baffoe-Bonnie³, Joan Morny⁴ and Christhopher Haas³, ¹MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ²MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, CA, ³MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, ⁴Piedmont Athens Regional Internal Medicine Residency Program, Athens, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…
Abstract Number: 1506 • ACR Convergence 2025
Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Olivia A. Stein¹, Jennifer Lee¹, Evelyne Vinet², Arielle Mendel³, Christian Pineau⁴, Leanne Mielczarek⁵ and Sasha Bernatsky², ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵Lupus Canada, Newmarket, Canada
Background/Purpose: Our objective is to identify barriers and facilitators perceived by people with systemic lupus erythematosus (SLE) regarding participation in clinical trials for novel/advanced agents,…
Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…
Abstract Number: 1517 • ACR Convergence 2025
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Aijing Liu¹, Fei Chang² and Qiuhong Xu¹, ¹Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ²Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)
Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
Abstract Number: 1494 • ACR Convergence 2025
Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences
NILOFAR JAHAGHI¹, Michael Golding², Fareha Nishat³, Kaitlyn Merrill², Diane Lacaille⁴, Umut Oguzoglu², Roberta Woodgate², Jennifer Stinson⁵, Christine Peschken⁶, Zahi Touma⁷, Jennifer Protudjer² and Lily Lim⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Manitoba, Winnipeg, Canada, ³University of Toronto, Toronto, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Young adulthood (18-30 years) is a life stage with many transitions. Young adults with Systemic Lupus Erythematosus must navigate this period while living with…
Abstract Number: 1477 • ACR Convergence 2025
Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Beste Acar¹, Berkay Aktas¹, Oguzhan Omer Kizilkaya¹, Zekayi Kutlubay² and serdal Ugurlu³, ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Dermatology, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: This study evaluates the contributions of large language models (LLMs) in clinical decision-making for atypical presentations of systemic lupus erythematosus (SLE). It focuses on…
Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Kristina Ciaglia¹ and Magan Fosso², ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…
Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Jerik Leung¹, Tomika Caldwell², Paul Nietert³, Clara Dismuke⁴, Hetlena Johnson⁵, Edith Williams⁶ and Everette Keller³, ¹Emory University, Rollins School of Public Health, Atlanta, GA, ²Medical University of Souty Carolina, Charleston, ³Medical University of South Carolina, Charleston, SC, ⁴VA Palo Alto Health Care System, Menlo Park, ⁵Lupus Community Advocate/Researcher, Columbia, SC, ⁶University of Rochester Medical Center, Rochester, NY
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…
Abstract Number: 1044 • ACR Convergence 2025
Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Gunjan Rana¹, Mansi Mehta¹ and Joanne Cunha², ¹Saint Vincent Hospital, Worcester, MA, ²BROWN MEDICINE, BROWN UNIVERSITY, Riverside, RI
Background/Purpose: Hydroxychloroquine is a cornerstone in the treatment of Systemic Lupus Erythematosus (SLE), while corticosteroids and immunosuppressive agents are employed for moderate to severe disease…
Abstract Number: 0937 • ACR Convergence 2025
MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
Melodie Zaknoun¹, Doaa Tehawey¹, Baruh Polis¹ and Chaim Putterman², ¹Azrieli Faculty of Medicine, Safed, Israel, ²Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: Of the 19 ACR case definitions for NPSLE, seven involve the peripheral nervous system. MRL/lpr mice spontaneously develop anti-dsDNA antibodies, nephritis, and skin disease,…
Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Sawyer May¹, Lynn Price¹ and Ryan Rex², ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…
Abstract Number: 0644 • ACR Convergence 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Ioannis Parodis¹, Caroline Gordon², Joan Merrill³, Matthias Schneider⁴, Zahi Touma⁵, Teri Jimenez⁶, Thomas Morel⁷, Mina Nejati⁸, Christian Stach⁹, Christine de La Loge¹⁰ and Laurent arnaud¹¹, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶UCB, Raleigh, NC, ⁷UCB, Basel, Switzerland, ⁸Biogen, Cambridge, MA, ⁹UCB, Monheim am Rhein, Germany, ¹⁰UCB, Brussels, Belgium, ¹¹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: Fatigue, musculoskeletal pain, and joint stiffness are common manifestations of SLE, presenting considerable treatment challenges, particularly in addressing chronic fatigue. Dapirolizumab pegol (DZP) is…
Abstract Number: 0623 • ACR Convergence 2025
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Marco Martinez¹, Karen Roberts², Rosana Quintana³, Marina Scolnik⁴, Carmen Funes Soaje⁵, Paula Alba⁶, Veronica Saurit⁷, Mercedes Garcia⁸, GUILLERMO ARIEL BERBOTTO⁹, Inés Verónica Bellomio¹⁰, Mario Eduardo Kerzberg¹¹, Graciela Noemi Gomez¹², Cecilia Pisoni¹³, Vicente Juarez¹⁴, Ana Malvar¹⁵, Antonio Da Silva¹⁶, ODIRLEI MONTICIELO¹⁷, Henrique Mariz¹⁸, Francinne Ribeiro¹⁹, Eduardo Borba²⁰, Eloisa Bonfa²⁰, Edgard dos Reis-Neto²¹, Iris Guerra Herrera²², Maria Loreto Massardo²³, Gustavo Aroca-Martínez²⁴, Lorena Gómez Escorcia²⁵, Carlos Alberto Cañas²⁶, Gerardo Quintana-Lopez²⁷, Carlos Toro-Gutierrez²⁸, Mario Moreno Alvarez²⁹, MIGUEL SAAVEDRA³⁰, Margarita Portela Hernández³¹, Hilda Fragoso-Loyo³², Luis H Silveira³³, Ignacio García-De la Torre³⁴, Carlos Abud-Mendoza³⁵, Jorge Antonio Esquivel Valerio³⁶, Maria Isabel Acosta³⁷, Astrid Paats³⁸, Claudia S. Mora-Trujillo³⁹, Manuel Ugarte-Gil⁴⁰, Armando Calvo⁴¹, Roberto Muñoz-Louis⁴², Martin Rebella⁴³, Alvaro Danza⁴⁴, José Gomez-Puerta⁴⁵, Federico Zazzetti⁴⁶, Ashley Orillion⁴⁷, Guillermo Pons-Estel³ and Ingris del Pilar Pelaez Ballestas⁴⁸, ¹HGSZ No ⁹, Instituto Mexicano del Seguro Social, San Luis Potosí, México, Rioverde, Mexico, ²Instituto de Investigación, Rosario, Argentina, Wyomissing, PA, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁷Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁸Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ¹⁰Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹¹Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹²Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Don Torcuato, Argentina, ¹³CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹⁴Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁵Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁶Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Holzkirchen, Germany, ¹⁷Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁸Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁹Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, ²⁰Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²²Hospital del Salvador Santiago de Chile, Santiago, Chile, santiago, Chile, ²³Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁴Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁵Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁶Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁷Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogota, Colombia, ²⁸Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ²⁹Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁰Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³¹Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁴Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, ³⁵Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁶Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁷Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁸Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ³⁹Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴⁰Universidad Cientifica del Sur, Lima, Peru, ⁴¹Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴²Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴³Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁴Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴⁶Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁸Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico, Mexico, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Evidence from high-income countries suggests that socioeconomic status (SES) and environmental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].